Image guided evaluation of 212Pb-VMT-a-NET in metastatic Neuroendocrine tumors: Bio distribution and Dosimetry

被引：0
|
作者：
Malik, D. [1 ]
Thakral, P. [1 ]
Rana, N. [1 ]
Singh, N. [1 ]
Koley, M. [1 ]
Gupta, J. [1 ]
Thakrani, D. [1 ]
Kapoor, S. [2 ]
Das, S. S. [1 ]
Schultz, M. [2 ]
Sen, I. [1 ]
机构：
[1] Fortis Mem Res Inst FMRI, Gurugram, India
[2] Perspect Therapeut, Iowa City, IA USA
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2024年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EP-0929
引用
收藏
页码：S803 / S804
页数：2
相关论文
共 24 条
  • [11] Interim safety and efficacy data of [212Pb]VMT-α-NET in somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors (NETs).
    Wahl, Richard L.
    Anthony, Lowell Brian
    Solnes, Lilja B.
    Mehr, Samuel H.
    Baratto, Lucia
    Hanna, Alaa
    Yang, Wenjing M.
    Keefe, Stephen Michael
    Halfdanarson, Thorvardur Ragnar
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
  • [12] Preclinical evaluation of 212Pb-based alpha-particle therapy for neuroendocrine tumors: dosimetry and potential toxicities
    Lee, Dongyoul
    Graves, Stephen
    Liu, Dijie
    Wen, Hsiang
    Zepeda-Orozco, Diana
    Madsen, Mark
    Walsh, Susan
    Watkins, G.
    Menda, Yusuf
    Schultz, Michael
    Bushnell, David
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [13] 212Pb-VMT-(I)over-cap±-NET (I)over-cap±-PRRT planning based on 203Pb-VMT-(I)over-cap±-NET predictive dosimetry
    Graves, Stephen
    Bushnell, David
    Schultz, Michael
    Bodeker, Kellie
    Dillon, Joseph
    Menda, Yusuf
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [14] A Phase I/IIa of [212Pb]VMT-i i-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
    Prasad, Vikas
    Trikalinos, Nikolaos
    Hanna, Alaa
    Johnson, Frances
    Puhlmann, Markus
    Wahl, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [15] Dosimetry and Potential Toxicities of 212Pb-DOTATOC in a Preclinical Model: Towards Personalized Dosimetry Based Alpha-Particle Therapy for Neuroendocrine Tumors
    Lee, Dongyoul
    Graves, Stephen
    Liu, Dijie
    Wen, Hsiang
    Zepeda-Orozco, Diana
    Madsen, Mark
    Walsh, Susan
    Watkins, G.
    Menda, Yusuf
    Schultz, Michael
    Bushnell, David
    PANCREAS, 2020, 49 (03) : 475 - 475
  • [16] Optimal imaging timepoint for diagnostic performance of 203Pb-VMT-(I)over-cap±-NET SPECT/CT in neuroendocrine tumors
    Jain, Sanchay
    Graves, Stephen
    Bodeker, Kellie
    Gaimari-Varner, Kristin
    Chandrasekharan, Chandrikha
    Schultz, Michael
    Menda, Yusuf
    Bushnell, David
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [17] Pb203-AR-RMX conjugates for image-guided TAT of neuroendocrine tumors (NETs)
    Tworowska, Izabela
    Stallons, Tania
    Saidi, Amal
    Wagh, Nilesh
    Rojas-Quijano, Federico
    Jurek, Paul
    Kiefer, Garry
    Torgue, Julien
    Delpassand, Ebrahim
    CANCER RESEARCH, 2017, 77
  • [18] Image guided therapy of SSTR (+)-neuroendocrine tumors (NETS) using 203Pb-labeled octreotate analog
    Tworowska, Izabela
    Stallons, Tania
    Saidi, Amal
    Wagh, Nilesh
    Rojas-Quijano, Federico
    Jurek, Paul
    Kiefer, Garry
    Delpassand, Ebrahim
    Torgue, Julien
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [19] Prevalence and Distribution of Metastatic Spread in Well Differentiated Neuroendocrine Tumors: Data from a Large Multicentric Italian Database (NET Management Study)
    Ferolla, P.
    Faggiano, A.
    Grimaldi, F.
    Valcavi, R. M.
    Manzoni, M.
    Davi, M., V
    De Marinis, L.
    Giuffrida, D.
    Ferone, D.
    Papini, E.
    Arnaldi, G.
    Fanciulli, G.
    Tomassetti, P.
    Colao, A.
    NEUROENDOCRINOLOGY, 2009, 90 (01) : 111 - 111
  • [20] Targeted a-Emitter Therapy with 212Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial
    Delpassand, Ebrahim S.
    Tworowska, Izabela
    Esfandiari, Rouzbeh
    Torgue, Julien
    Hurt, Jason
    Shafie, Afshin
    Nunez, Rodolfo
    JOURNAL OF NUCLEAR MEDICINE, 2022, 63 (09) : 1326 - 1333
123